The Community Guide

- gsearch

Search Results

Narrow Results:

2021 1
2018 1

AIDS Clinical Trials Group and the Tuberculosis Trials Consortium 1

Journal Article 2

1 - 2 of 2 Results

Refine Results

Refine Results:

Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy

CITE Title : Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy Personal Author(s) : Haaland, Richard E.;Otieno, Kephas;Martin, Amy;Katana, Abraham;Dinh, Chuong;Slutsker, Laurence;Menendez, Clara;Gonzalez, Raquel;Williamson, John;Heneine, Walid;Desai, Meghna; Published Date : Oct 17 2018 Source : AIDS Res Hum Retroviruses. 2018; 34(11):912-915. URL : https://stacks.cdc.gov/view/cdc/60780 Haaland, Richard E. et al. (2018). Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. 34(11). Haaland, Richard E. et al. "Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy" 34, no. 11 (2018) Haaland, Richard E. et al. "Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy" vol. 34, no. 11, 2018 Export RIS Citation Information.

:

Haaland, Richard E. ;

Otieno, Kephas

Oct 17 2018 | AIDS Res Hum Retroviruses. 2018; 34(11):912-915.

:

Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an un...
Central Monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis

CITE Title : Central Monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis Personal Author(s) : Bryant, Kia E.;Yuan, Yan;Engle, Melissa;Kurbatova, Ekaterina V.;Allen-Blige, Cynthia;Batra, Kumar;Brown, Nicole E.;Chiu, Kuo wei;Davis, Howard;Elskamp, Mascha;Fagley, Melissa;Fedrick, Pamela;Hedges, Kimberly NC;Narunsky, Kim;Nassali, Joanita;Phan, Mimi;Phan, Ha;Purfield, Anne E.;Ricaldi, Jessica N.;Robergeau-Hunt, Kathleen;Whitworth, William C.;Sizemore, Erin E.; Corporate Authors(s) : AIDS Clinical Trials Group and the Tuberculosis Trials Consortium Published Date : 5 2021 Source : Contemp Clin Trials. 104:106355 URL : https://stacks.cdc.gov/view/cdc/116842 Bryant, Kia E. et al. (2021). Central Monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis. 104 Bryant, Kia E. et al. "Central Monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis" 104 (2021) Bryant, Kia E. et al. "Central Monitoring in a randomized, open-label, controlled phase 3 clinical trial for a treatment-shortening regimen for pulmonary tuberculosis" vol. 104, 2021 Export RIS Citation Information.

:

Bryant, Kia E. ;

Yuan, Yan

5 2021 | Contemp Clin Trials. 104:106355

:

Introduction:With the growing use of online study management systems and rapid availability of data, timely data review and quality assessments are ne...